Impact Biomedical Stock Set to Reverse Split on Wednesday, September 23rd (NYSEAMERICAN:IBO)

Shares of Impact Biomedical Inc. (NYSEAMERICAN:IBO – Free Report) are set to reverse split before the market opens on Wednesday, September 23rd. The 1-12.62 reverse split was recently announced. The number of shares owned by shareholders will be adjusted after the closing bell on Tuesday, September 22nd.

Impact Biomedical Price Performance

IBO opened at $0.48 on Tuesday. Impact Biomedical has a 1 year low of $0.37 and a 1 year high of $0.83. The firm has a 50 day moving average price of $0.46 and a 200 day moving average price of $0.52.

Get Impact Biomedical alerts:

Impact Biomedical Company Profile

(Get Free Report)

Impact Biomedical, Inc (“IBIO”) currently is a holding company operating mainly through our majority owned subsidiary, Global BioLife, Inc, which was incorporated on April 14, 2017. The Company is committed to both funding research and developing intellectual property portfolio. We currently focus on research in three main areas: (i) development of a universal therapeutic drug platform; (ii) a new sugar substitute; and (iii) a multi-use fragrance. IBIO discovers, confirms, and patents unique science and technologies which can be developed into new offerings in human healthcare and wellness in collaboration with external partners through licensing, co-development, joint ventures, and other relationships.

Featured Articles

• Five stocks we like better than Impact Biomedical
• Analysts Are Punting Their Calls Into the Next Quarter After Adobe’s Mixed Earnings
• Institutional Money Is Pouring Into These 2 Altcoin ETFs
• The End of Big Tech Buybacks? Only One Hyperscaler Is Still Repurchasing Shares
• 3 Dividend Kings to Buy While They’re Still Beaten Down

Receive News & Ratings for Impact Biomedical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Impact Biomedical and related companies with MarketBeat.com's FREE daily email newsletter.